UK markets open in 2 hours 51 minutes

Mesoblast Limited (MSB.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.3350-0.0050 (-1.47%)
As of 03:48PM AEDT. Market open.
Full screen
Previous close0.3400
Open0.3350
Bid0.3350 x 1092600
Ask0.3400 x 5097500
Day's range0.3300 - 0.3450
52-week range0.2550 - 1.3511
Volume3,196,919
Avg. volume3,926,033
Market cap339.958M
Beta (5Y monthly)2.48
PE ratio (TTM)N/A
EPS (TTM)-0.1300
Earnings date29 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.62
  • GlobeNewswire

    Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

    NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer). Together the entitlement offer and institutional placement raised gross proceeds of A$97 million, including A$36.7 million committed today on the same terms as

  • GlobeNewswire

    United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

    NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD). FDA provided this feedback in formal minutes to

  • Insider Monkey

    Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript

    Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript February 29, 2024 Mesoblast Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Silviu Itescu: Good morning, good afternoon to Mesoblast’s Financial Results and Operational Update for the Half Year ended December 31, […]